Abstract
Bio-pharmaceutics is one of the most science-intensive industries. Annually a lot of money is spent on applied research aimed at development and commercialization of new medications. Many pharmaceutical companies try to have in their product line or pipeline drugs on the basis of monoclonal antibodies, i.e. a class of biotechnological preparations that are used to combat oncologic and autoimmune diseases and are based on target therapy principle. Because of the high interest in bio-pharmaceutical industry on the part of businessmen, state and science any advanced data dealing with the situation inside the market can be useful for shaping the adequate picture of the present day condition and for making managerial decisions on state and private level. The article provides information about global sales of preparations based on monoclonal antibodies. Apart from sales in terms of money the author calculates the natural volume of products being sold based on price analysis of products. The article gives a list of preparations registered on EU and US markets rated by their sales. By analyzing preparation prices corrected to dosage it was possible to find the most expensive and the cheapest medications in their class. Information concerning the natural volume of drug being sold can help understand the scale of preparation production.
Highlights
Bio-pharmaceutics is one of the most science-intensive industries
Many pharmaceutical companies try to have in their product line or pipeline drugs on the basis of monoclonal antibodies, i.e. a class of biotechnological preparations that are used to combat oncologic and autoimmune diseases and are based on target therapy principle
Because of the high interest in bio-pharmaceutical industry on the part of businessmen, state and science any advanced data dealing with the situation inside the market can be useful for shaping the adequate picture of the present day condition and for making managerial decisions on state and private level
Summary
Методы исследования Исследование предполагало сбор и обработку информации, касающейся торговых наименований препаратов на основе моноклональных антител, представленных на мировом рынке. В ходе исследования не удалось получить информацию об объеме продаж препаратов, которыми владеют частные компании, однако наиболее значимые для исследования препараты в анализе представлены. Продажи препаратов на основе моноклональных антител Количество препаратов, зарегистрированных в регуляторных органах США и ЕС, составляет 130 наименований, которые включают оригинальные препараты и биоаналоги, а также моноклональные антитела и их фрагменты, конъюгаты моноклональных антител и некоторые другие нестандартные варианты препаратов. Публичные компании реализовали препаратов на основе моноклональных антител на 121,8 млрд долларов Объем всего рынка подобных препаратов составлял 115,2 млрд долларов [9]). Что за год продажи данного препарата выросли практически на 4 млрд долларов (55%) по сравнению с 2018 г. «Имфинзи» (132%, или 0,8 млрд долларов). жи которого возросли на 62% (1,4 млрд Также нужно отметить «Окревус», прода- долларов)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
